While these are often much cheaper, they are not FDA-approved generics
Morris G, Walder K, Berk M, Carvahlo AF, Marx W, Bortolasci CC, et al
Both classes lower blood glucose, promote weight loss, and reduce cardiovascular risk, but SGLT2 inhibitors have stronger evidence for kidney and heart failure protection and are generally preferred in those conditions
The PIONEER-1 study (2019) demonstrated significant improvements in blood glucose in patients with Type 2 diabetes, with mild-to-moderate gastrointestinal side effects and dramatic weight loss at higher doses
Always consult your healthcare provider before changing your diet, exercise routine, or medication regimen
Structure beats restriction